Literature DB >> 6827108

A simple immunoradiometric assay for the terminal SC5b-9 complex of human complement.

S Bhakdi, M Muhly.   

Abstract

Complement activation in serum via classical or alternative pathway results in the formation of a water-soluble, macromolecular SC5b-9 protein complex consisting of non-covalently associated C5b-C9 complement components and serum S-protein. Characteristic neoantigens are expressed on this complex that permit its immunological differentiation from native complement proteins. The present paper describes a procedure for isolating radiolabelled, specific antibodies to C5b-9 neoantigens. With the use of these antibodies, a simple and rapid immunoradiometric assay for SC5b-9 has been developed that allows for detection of 3-4 micrograms SC5b-9 in 1 ml human serum or plasma. The method is suitable for routine screening analyses for SC5b-9 in patients' plasma, and for detection of SC5b-9 experimentally generated in vitro.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6827108     DOI: 10.1016/0022-1759(83)90088-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  11 in total

1.  Plasma levels of soluble membrane attack complex are elevated despite viral suppression in HIV patients with poor immune reconstitution.

Authors:  T N Schein; T E Blackburn; S L Heath; S R Barnum
Journal:  Clin Exp Immunol       Date:  2019-09-08       Impact factor: 4.330

2.  Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.

Authors:  S Bhakdi; R Käflein; T S Halstensen; F Hugo; K T Preissner; T E Mollnes
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

3.  Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex.

Authors:  J Bariety; N Hinglais; S Bhakdi; C Mandet; M Rouchon; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

4.  Immunohistochemical detection of the terminal C5b-9 complement complex in children with glomerular diseases.

Authors:  H G Rus; F Niculescu; M Nanulescu; A Cristea; P Florescu
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

5.  Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.

Authors:  F Niculescu; F Hugo; H G Rus; R Vlaicu; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

6.  Immunohistochemical alterations after muscle trauma.

Authors:  G Fechner; T Bajanowski; B Brinkmann
Journal:  Int J Legal Med       Date:  1993       Impact factor: 2.686

7.  Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.

Authors:  I Horigome; J Seino; K Sudo; Y Kinoshita; T Saito; K Yoshinaga
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

8.  In vivo clearance studies of the terminal fluid-phase complement complex in rabbits.

Authors:  F Hugo; C Berstecher; S Krämer; W Fassbender; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

9.  Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium.

Authors:  F Hugo; T Hamdoch; D Mathey; H Schäfer; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

Review 10.  Soluble Membrane Attack Complex: Biochemistry and Immunobiology.

Authors:  Scott R Barnum; Doryen Bubeck; Theresa N Schein
Journal:  Front Immunol       Date:  2020-11-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.